Intravenous Contrast Computed Tomography Versus Native Computed Tomography in Patients With Acute Abdomen and Impaired Renal Function

Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · Dec 11, 2019

Keywords

ClinConnect Summary

The INCARO trial is studying the safety and effectiveness of two types of CT scans for patients with acute abdominal pain who have impaired kidney function. One type of scan uses a special dye called intravenous (IV) contrast to get clearer images, while the other type uses no contrast at all. Researchers want to see if using the IV contrast increases the risk of kidney damage or other serious health issues within 90 days after the scan.

To be eligible for this trial, participants must be adults aged 18 or older who need an emergency CT scan for abdominal issues and have a certain level of kidney function (measured as eGFR between 15 and 45 ml/min). Patients with severe kidney problems, recent kidney treatments, or certain other medical conditions won't be included. If you join the study, you’ll be randomly assigned to receive either the contrast-enhanced CT or the non-contrast CT, and researchers will monitor your health outcomes after the scan. This research aims to provide clearer answers about the safety of using IV contrast in patients with existing kidney issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients requiring emergency abdominal or body CT with eGFR 15-45 ml/min/1.73 m2
• Exclusion Criteria:
• • Age less than 18 years
• • Pregnancy
• • eGFR less than 15 or more than 45 ml/min/1.73 m2
• • Renal replacement therapy within 30 days prior enrolment
• • CT with IV contrast less than 72 hours prior enrolment
• • Suspicion of vascular occlusion, dissection or bleeding (i.e. need for IV-contrast)
• • CT needed without IV-contrast to detect or rule out ureteral stone
• • IV contrast allergy
• • Inability to give written consent.